Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Halo Healthcare Inc.

Early detection of breast cancer

This article was originally published in Start Up

Executive Summary

A women’s health care company in turnaround – one well recognized for assessing a woman’s risk of developing breast cancer through the HALO breast test – is developing a breast cancer diagnostic based on the presence of three protein biomarkers found in breast nipple aspirate fluid. The HALO Pivot diagnostic kit from Halo Healthcare Inc. is an in-office, noninvasive test for diagnosing cancer or a recurrence at a very early stage.

You may also be interested in...



The EU’s New Batteries Regulation: When And How Its Requirements Will Impact Medtech

The EU Batteries Regulation is yet another legal instrument medical device manufacturers must address over the coming years alongside the core Medical Device and IVD Regulations.

Mental Health Top Of Mind For Increasingly Health-Anxious Brits, Kaizo Survey Finds

Worryingly, however, British consumers are also increasingly turning to social media for health information, and rejecting it if it conflicts with what they believe, or if it is not based on personal experience. 

Kymera Puts Emphasis On Immunology In New Growth Phase

CEO Nello Mainolfi talked to Scrip about Kymera’s pipeline expansion, which will prioritize oral targeted protein degraders in immunology, including two new assets moving into the clinic.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037772

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel